Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BI-4020 is a fourth-generation, orally active, and non-covalent inhibitor of EGFR tyrosine kinase. BI-4020 exhibits activity agains the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines), the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM) and EGFR wt (IC50=190 nM). BI-4020 exhibits high kinome selectivity and good DMPK properties.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 66,000 |
5 mg | 在庫あり | ¥ 160,000 |
10 mg | 在庫あり | ¥ 228,500 |
25 mg | 在庫あり | ¥ 342,000 |
50 mg | 在庫あり | ¥ 457,000 |
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 195,500 |
ターゲット&IC50 | EGFR (WT):190 nM, EGFR (T790M/C797S/del19):0.2 nM, EGFR (del19):1 nM |
分子量 | 542.68 |
分子式 | C30H38N8O2 |
CAS No. | 2664214-60-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 240 mg/mL (442.25 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BI-4020 2664214-60-0 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR HER1 inhibit BI4020 BI 4020 Epidermal growth factor receptor ErbB-1 Inhibitor inhibitor